Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis

Among persons with tuberculous meningitis, no evidence of beneficial effect from high-dose rifampin was observed, and the potential for a harmful effect cannot be ruled out. (Funded by the U.K. Medical Research Council and others; ISRCTN Registry number, ISRCTN15668391.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2025-12-17
DOI
https://doi.org/10.1056/nejmoa2502866
Citations
7
Primary Topic
Infectious Diseases and Tuberculosis
Type
article
Field-Weighted Citation Impact
14.04
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis

Ananta Bangdiwala, Vycke Yunivita, Elin M. Svensson, Nicole Engen et al.
7 citations
New England Journal of Medicine
Infectious Diseases and Tuberculosis
14.04
article

Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis

Ananta Bangdiwala, Vycke Yunivita, Elin M. Svensson, Nicole Engen, Reinout van Crevel, Timothy Mugabi, David R. Boulware, Enock Kagimu, Ahmad Rizal Ganiem, Sylvia Namanda, Lindsey te Brake, Nathan C. Bahr, Lillian Tugume, Noveline Sagita, Biyue Dai, Darma Imran, Kogieleum Naidoo, Jane Gakuru, Maula Nuruddin Gaharu, Mable Kabahubya, Richard Lessells, Abdu K Musubire, Fiona V Cresswell, Kartika Maharani, Rob E. Aarnoutse, Raph L Hamers, Rovina Ruslami, Suzaan Marais, Sarah Kimuda, Suzan Namombwe, Riwanti Estiasari, David B. Meya, Mahomed Yunus Suleman Moosa, Bongeka Hlabisa, Media Yuni Kurniawati
article en
7 citations

Abstract

Among persons with tuberculous meningitis, no evidence of beneficial effect from high-dose rifampin was observed, and the potential for a harmful effect cannot be ruled out. (Funded by the U.K. Medical Research Council and others; ISRCTN Registry number, ISRCTN15668391.).

New England Journal of MedicineVol. 393(24)
Brighton and Sussex Medical School (GB), South African Medical Research Council (ZA), Uppsala University (SE), CHI Health Immanuel (US), University of Minnesota (US), Radboud University Nijmegen (NL), University of Cape Town (ZA), Queen Mary University of London (GB), Centre for the AIDS Programme of Research in South Africa (ZA), Care Institute of Medical Sciences (IN), Radboud University Medical Center (NL), University of Indonesia (ID), University of Oxford (GB), Dr. Hasan Sadikin General Hospital (ID), London School of Hygiene & Tropical Medicine (GB), Universitas Bhayangkara Jakarta Raya (ID), Radboud Institute for Molecular Life Sciences (NL), Infectious Diseases Institute (UG), Universitas Kristen Immanuel (ID), Bandung Islamic University (ID), Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo (ID), Oxford University Clinical Research Unit Indonesia, Makerere University (UG), Padjadjaran University (ID), University of KwaZulu-Natal (ZA)
Openalex Percentile: Top 1%
Infectious Diseases and Tuberculosis
14.04
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.